hVIVO plc

Symbol: HVO.L

LSE

20.3

GBp

Market price today

  • -175.5175

    P/E Ratio

  • -840.3567

    PEG Ratio

  • 138.12M

    MRK Cap

  • 0.02%

    DIV Yield

hVIVO plc (HVO-L) Stock Price & Analysis

Shares Outstanding

680.37M

Gross Profit Margin

1.00%

Operating Profit Margin

0.12%

Net Profit Margin

-0.02%

Return on Assets

-0.02%

Return on Equity

-0.04%

Return on Capital Employed

0.28%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Yamin Mohammed Khan Ph.D.
Full-time employees:210
City:London
Address:21 Plumbers Row
IPO:2012-12-14
CIK:

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

General Outlook

In simple terms, hVIVO plc has 680.372 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.124%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.016%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.015% return, is a testament to hVIVO plc's adeptness in optimizing resource deployment. hVIVO plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.038%. Furthermore, the proficiency of hVIVO plc in capital utilization is underscored by a remarkable 0.279% return on capital employed.

Stock Prices

hVIVO plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $18.5, while its low point bottomed out at $18. This variance in figures offers investors a lucid insight into the roller-coaster ride that is hVIVO plc's stock market.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of hVIVO plc (HVO.L) on the LSE in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -175.518 in 2023.

What is the ticker symbol of hVIVO plc stock?

The ticker symbol of hVIVO plc stock is HVO.L.

What is company IPO date?

IPO date of hVIVO plc is 2012-12-14.

What is company current share price?

Current share price is 20.300 GBp.

What is stock market cap today?

The market cap of stock today is 138115510.000.

What is PEG ratio in 2023?

The current -840.357 is -840.357 in 2023.

What is the number of employees in 2023?

In 2023 the company has 210.